Browse by author
Lookup NU author(s): Dr James KnightORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Copyright © 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc. A prominent feature of many human cancers is oncogene-driven activation of the DNA damage response (DDR) during early tumorigenesis. It has been shown previously that noninvasive imaging of the phosphorylated histone H2A variant H2AX, γH2AX, a DNA damage signaling protein, is possible using 111In-labeled anti-γH2AX antibody conjugated to the cell-penetrating peptide transactivator of transcription (TAT). The purpose of this study was to investigate whether 111In-anti-γH2AX-TAT detects the DDR during mammary oncogenesis in BALB-neuT mice. Methods: Mammary fat pads from BALB-neuT and wild-type mice (age, 40-106 d) were immunostained for γH2AX. 111In-anti-γH2AX-TAT or a control probe was administered intravenously to BALB-neuT mice. SPECT was performed weekly and compared with tumor detection using palpation and dynamic contrast-enhanced MR imaging. Results: γH2AX expression was elevated in hyperplastic lesions in the mammary fat pads of BALB-neuT mice aged 76-106 d, compared with normal fat pads from younger mice and carcinomas from older mice (13.5 ± 1.2 γH2AX foci/cell vs. 5.2 ± 1.5 [P < 0.05] and 3.4 ± 1.1 [P < 0.001], respectively). Serial SPECT imaging revealed a 2.5-fold increase in 111In-anti-γH2AX-TAT accumulation in the mammary fat pads of mice aged 76-106 d, compared with control probe (P = 0.01). The median time to detection of neoplastic lesions by 111In-anti-γH2AX-TAT (defined as >5% injected dose per gram of tissue) was 96 d, compared with 120 and 131 d for dynamic contrast-enhanced MR imaging and palpation, respectively (P < 0.001). Conclusion: DDR imaging using 111In-anti-γH2AX-TAT identified mammary tumors significantly earlier than MR imaging. Imaging the DDR holds promise for the detection of preneoplasia and as a technique for screening cancer-prone individuals.
Author(s): Cornelissen B, Able S, Kartsonaki C, Kersemans V, Allen PD, Cavallo F, Cazier J-B, Iezzi M, Knight J, Muschel R, Smart S, Vallis KA
Publication type: Article
Publication status: Published
Journal: Journal of Nuclear Medicine
Year: 2014
Volume: 55
Issue: 12
Pages: 2026-2031
Print publication date: 01/12/2014
Online publication date: 13/11/2014
Acceptance date: 01/01/1900
ISSN (print): 0161-5505
ISSN (electronic): 2159-662X
Publisher: Society of Nuclear Medicine Inc.
URL: https://doi.org/10.2967/jnumed.114.142083
DOI: 10.2967/jnumed.114.142083
PubMed id: 25453049
Altmetrics provided by Altmetric
